Skip to main content
. 2019 Apr 2;36(7):1756–1769. doi: 10.1007/s12325-019-00940-7

Fig. 2.

Fig. 2

Mean ACT scores* (a) and ACT asthma control categories reported (b) at baseline (visit 1) and visit 3 (on-treatment population; n = 117). *Data are presented as mean (95% CI); Categories defined according to 2018 GINA guidelines (1); P value refers to mixed linear model of change from baseline (visit 1) to visit 3 (week 12 of treatment). Treatment with B/F Turbuhaler® and B/F Easyhaler® evaluated at visit 1 and 3, respectively. ACT Asthma Control Test, ANOVA analysis of variance, GINA Global Initiative for Asthma, B/F budesonide and formoterol fumarate